Skip to content

CapEx at other companies

Eli Lilly logo
Eli LillyLLY
$2.33B+54.0%
Medtronic logo
MedtronicMDT
$488M+6.3%
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
$42.7M-40.1%
Abbott logo
AbbottABT
$399M-17.6%
Viatris logo
ViatrisVTRS
$39.9M-6.3%

Other financials

Income statement

See full
Revenue$761.7M+33.9%
Gross profit$529.0M+29.3%
Operating income$122.1M+37.5%
Net income$91.1M+157%
EPS (diluted)$1.30+160%

Balance sheet

See full
Cash & equivalents$480.4M-62.6%
Total debt$969.7M-45.5%
Total equity$1.3B-2.1%
Total assets$3.0B-15.1%

Cash flow

See full
Operating cash flow$113.8M+78.4%
Free cash flow$89.5M+73.8%

Valuation

See full
Market cap$10.1B-19.9%
Enterprise value$10.59B-19.4%
P/E33.3×+2.0×
P/S3.5×-2.3×

Profitability

See full
Gross margin71%+0.6pp
Operating margin17.5%+2.0pp
Net margin10.4%-7.9pp
FCF margin14.3%+1.1pp

Returns & leverage

See full
Return on equity23%-14.9pp
Debt / equity0.7×-0.6×
Current ratio2.5×-2.0×

Where this comes from

Reported directly by Insulet in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insulet's capex.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Insulet's capex?
Insulet (PODD) reported capex of $24.3M in Q1 2026.
How has Insulet's capex changed year-over-year?
Insulet's capex increased by 97.6% year-over-year, from $12.3M to $24.3M.
What is the long-term trend for Insulet's capex?
Over 4 years (2021 to 2025), Insulet's capex has grown at a 14.4% compound annual growth rate (CAGR), from $111.9M to $191.6M.
What does capex mean?
Cash spent on long-term physical assets to support business operations.
How do you interpret capex?
High spending signals growth investment, while low spending may indicate maintenance-only mode or capital efficiency.
How does capex compare across companies?
Common across all capital-intensive industries; peers in medical device manufacturing often have high CapEx for production facilities.